Efficacy and safety of intravenous nimodipine administration for treatment of hypertension in patients with intracerebral hemorrhage

Yuqian Li1,*
Wei Fang1,*
Lei Tao2,*
Min Li1
Yanlong Yang1
Yafei Gao1
Shunnan Ge1
Li Gao1
Bin Zhang1
Zhihong Li1
Wei Zhou1
Boliang Wang2
Lihong Li1

1Department of Neurosurgery, 2Department of Anesthesiology, 3Department of Emergency, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China

*These authors contributed equally to this study

Background: Nicardipine (NC) is the most commonly used antihypertensive drug in neurological patients with hypertension. Although nimodipine (NM) is widely used to treat cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage, trials exploring its antihypertensive effect after intravenous administration in subjects with intracerebral hemorrhage (ICH) are scarce.

Methods: A retrospective study was carried out to compare the safety and efficacy of NC and NM administered intravenously in patients with ICH. Therapeutic responses were assessed by achievement of goal blood pressure (BP); use of additional medications for BP control; proportion of time spent within goal; variability in BP; time to goal BP; number of dose adjustments; variability in ICH volume, Glasgow Coma Scale score, and intracranial pressure; and drug-related complications.

Results: A total of 87 patients were eligible for analysis (n=46 [NC]; n=41 [NM]), and baseline characteristics between groups were similar. Both agents were effective in achieving goal BP during infusion, with 93.5% and 87.8% patients in the NC and NM groups achieving goal, respectively. Fewer additional medications were needed to control BP in the NC group. BP variability was similar and no differences were observed in the mean time to goal BP and mean numbers of dose adjustments between both groups. Interestingly, intracranial pressure declined (P=0.048) during NC administration but increased (P=0.066) after NM treatment. Finally, the incidences of hematoma expansion, neurological deterioration, and adverse drug events were similar in both groups.

Conclusion: NM is effective and safe for BP control in patients with ICH.

Keywords: nimodipine, blood pressure, intravenous infusion

Introduction

Spontaneous, nontraumatic intracerebral hemorrhage (ICH) leads to high morbidity and mortality worldwide. Indeed, ICH accounts for 10%–17% of all strokes.1-4 In the United States, 37,000–52,400 people suffer from ICH each year.5 The median 1-month case lethality rate is 40%, and only 12% to 39% of patients achieve functional independence.6 Hypertension, the most common risk factor for ICH, is observed in 70% to 80% of patients with ICH.5 Furthermore, in patients with ICH, elevated blood pressure (BP) results in hematoma expansion and rebleeding at 3 months,7,8 which subsequently leads to poor outcomes. Previous studies have identified elevated BP, especially systolic BP (SBP) over 200 mmHg, as an important risk factor for bleeding in primary and recurrent ICH.5,9-12 These findings indicate the serious threat related to BP. The aim of antihypertensive therapy is to lower BP quickly but safely, avoiding complications. Since intravenous (IV) nicardipine (NC) is feasible...
and safe to treat hypertension in neurological patients with unfavorable outcome, it is recommended as a first-line agent in neurological intensive care unit (NICU) settings in the United States.\textsuperscript{13,14}

Nimodipine (NM), an L-type calcium channel antagonist, is recommended in the prevention and treatment of cerebral vasospasm, and Class I data only exist for its use in aneurysmal subarachnoid hemorrhage.\textsuperscript{13} Treatment with NM reduces the severity of neurological deficits resulting from vasospasm in subarachnoid hemorrhage patients. However, the BP-lowering effects of IV NM should not be minimized, a clinical study has documented lowering BP in patients after acute stroke.\textsuperscript{15} Like other calcium channel blockers, such as NC, NM has antihypertensive effects – its main mechanism of action is vasodilatation, which causes decreased peripheral vascular resistance.\textsuperscript{16}

Previous study has demonstrated that IV infusion of NM leads to BP lowering in patients with acute stroke.\textsuperscript{15} In our clinical work, we found that IV NM rapidly lowered BP. Despite the antihypertensive effect of NM administered intravenously, trials exploring the efficacy and safety of IV NM for treating hypertension in neurological patients with ICH are scarce, and no direct comparison between NC and NM delivered as continuous infusions in strictly ICH patients has been reported. We hypothesized that there were no differences in efficacy and safety profile between continuous infusions of NM and NC for management of hypertension in patients with ICH.

Patients and methods

Patients

A total of 87 patients were enrolled in this study performed between June 2013 and March 2014 in the NICU of Fourth Military Medical University Tangdu Hospital. As it was a retrospective study, neither informed consent nor approval of the ethics committee was needed. Admission data collected from each eligible patient included race; age; sex; weight; heart rate (HR); history of smoking, alcohol consumption, diabetes and hypertension; intracranial pressure (ICP); Glasgow Coma Scale (GCS) score; SBP; and intracerebral hemorrhage (ICH) volume. The inclusion and exclusion criteria used in this study are summarized in Table 1.

General care

All patients received the standard intensive care management. Critically ill patients with GCS scores <9 were mechanically ventilated. If necessary, patients were treated with midazolam (0.2 mg/kg/h, increased as needed) for sedation and fentanyl (2 μg/kg/h, increased as needed) for analgesia. Besides, blood glucose values were kept between 6–10 mmol/L and the core temperature between 36.0 °C and 37.0 °C. Blood gases were tested at least once a day to avoid hypercarbia, hypoxemia or electrolyte imbalance. During a period of infusion, cerebral perfusion pressure (CPP) was kept at $\geq 70$ mmHg. Central venous pressure (CVP) was maintained between 4 and 12 cm H$_2$O to avoid hypervolemia or hypovolemia. Mannitol

### Table 1 Inclusion and exclusion criteria in the study

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. ICH</td>
<td>1. BP readings documented less frequently than every 10 minutes</td>
</tr>
<tr>
<td>2. Patients whose elevated SBP at admission reached $&gt;140$ mmHg</td>
<td>2. Admission SBP $&gt;240$ mmHg</td>
</tr>
<tr>
<td>3. Aged 18 years or older and less than 90 years</td>
<td>3. Intraventricular or infratentorial hemorrhage</td>
</tr>
<tr>
<td>4. Patients who received ventricular ICP monitors</td>
<td>4. Clinical and radiological signs of brain herniation</td>
</tr>
<tr>
<td>5. The total GCS score (aggregate of verbal, eye, and motor response scores) of 5 to 15 at time of enrollment</td>
<td>5. TBI and aSAH</td>
</tr>
<tr>
<td>6. CT scan demonstrated intraparenchymal hematoma with manual hematoma volume measurement $&lt;60$ mL ([length x width x height]/2)</td>
<td>6. Patients with coagulopathy</td>
</tr>
<tr>
<td></td>
<td>7. Patients who received any intravenous antihypertensives prior to the NICU</td>
</tr>
<tr>
<td></td>
<td>8. Uncontrollable irritability, pain, or other factors that affect BP</td>
</tr>
<tr>
<td></td>
<td>9. Any history of congestive heart failure, renal failure, or liver damage</td>
</tr>
<tr>
<td></td>
<td>10. Pregnancy, lactation, or parturition</td>
</tr>
<tr>
<td></td>
<td>11. Known sensitivity to nicardipine or nimodipine</td>
</tr>
</tbody>
</table>

Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; BP, blood pressure; CT, computed tomography; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; ICP, intracranial pressure; NICU, neurological intensive care unit; SBP, systolic blood pressure; TBI, traumatic brain injury.
(20%), at a dose of 0.25 to 1 g/kg, was given as an IV bolus in patients with ICP $\geq 20$ mmHg. Surgery was considered if the ICP remained at $>20$ mmHg for 30 minutes.

**Methods**

A retrospective study was conducted with patients showing SBP $>140$ mmHg – the goal for BP was to reduce and maintain SBP between 120 and 140 mmHg. Patients were administered either NC (n=46) or NM (n=41), intravenously from admission. The following antihypertensive management protocol was used (Figure 1): NC was administered as a continuous infusion with an hourly starting dose of 2 mg/h; if the BP goal was not achieved, the dose was increased by 2 mg/h every 10 minutes as needed, up to a maximum of 15 mg/h. The use was limited when side effects appeared before the maximum dose was reached. Likewise, NM was administered at a starting dose of 1 mg/h, and the dose was increased by 0.5 mg/h every 10 minutes, up to a maximum of 4 mg/h. Once the BP fell below 140 mmHg, IV drug amounts were gradually reduced, and if there was any rebound effect, we returned and maintained the drug to control BP. Nitroprusside was administered if the SBP was still greater than 140 mmHg 30 minutes after the maximum dose had been given. If side effects associated with both drugs limited their use during infusion, antihypertensive medications were discontinued. No patients in either group had oral antihypertensive medications during this period.

**Statistical analysis**

The Kolmogorov–Smirnov test was used to assess the distribution of continuous variables. Normally distributed data were reported as mean or mean percentage. The comparison of variables was carried out by independent-samples t-test or paired-samples t-test. Categorical variables were compared using the chi-square test. $P<0.05$ was considered statistically significant.

**Results**

**Patient characteristics**

A total of 87 Chinese patients were included in this study; of these, 46 patients received NC, with 32 patients within 6 hours of ICH symptom onset, while 41 individuals received NM, with 33 patients within 6 hours of symptom onset (Figure 2). Baseline characteristics were similar, with no

![Figure 1 Antihypertensive management protocol.](https://www.neuropsychiatricdiseaseandtreatment.com/images/figure1.png)

**Abbreviations:** BP, blood pressure; h, hour; ICH, intracerebral hemorrhage; IV, intravenous; SBP, systolic blood pressure.
significantly different between the groups initially. Overall, 61% and 54% were female in the NC and NM groups, respectively ($P=0.497$). The mean age was 62±9 years in the NC group and 60±8 years for NM patients ($P=0.684$). In addition, there was no statistical difference between both groups in baseline mean SBP (176±17 mmHg [NC] vs 172±19 mmHg [NM]) ($P=0.399$), mean HR (88±25 bpm [NC] vs 91±25 bpm [NM]) ($P=0.820$), or mean weight (62±10 kg [NC] vs 65±11 kg [NM]) ($P=0.523$). Further, the mean ICH volume was similar between both groups, with 29±11 mL obtained in NC subjects and 31±10 mL in the NM group ($P=0.352$). Moreover, no statistically significant difference was observed in mean GCS scores (9±3 [NC] vs 9±2 [NM]) ($P=0.417$) or ICP (18±8 mmHg [NC] vs 14±6 mmHg [NM]) ($P=0.186$) at admission (Table 2).

### Efficacy and safety

Electrocardiographic data were recorded for all patients treated with the present antihypertensive protocol after admission to the NICU. All patients had noninvasive monitoring devices to measure BP every 5 minutes, and all the values of ICP were acquired by ventricular ICP monitors. The hemodynamic indices recorded over time for both groups are shown in Figure 3 and Table 3. Interestingly, mean SBP significantly decreased after treatment with both drugs: administration of NC resulted in a significant reduction, from 176±17 mmHg at admission to 136±4 mmHg after 1 hour of infusion ($P<0.001$); likewise, mean SBP decreased from 172±19 mmHg to 138±8 mmHg after NM administration ($P<0.001$). Importantly, most patients treated with either agent achieved the SBP goal of 140 mmHg within 1 hour, which was steadily maintained during infusion. As for ICP, a decline from 18±8 mmHg, at admission, to 16±8 mmHg ($P=0.048$) was recorded during IV administration of NC, but this parameter slightly increased, from 14±6 mmHg to 16±5 mmHg, after NM treatment ($P=0.066$). Of note, HR was reduced in both groups, although neither treatment resulted in a statistically significant change ($P=0.121$ [NC]; $P=0.135$ [NM]).

### Table 2 Baseline characteristics of patients in the nicardipine and nimodipine groups

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Nicardipine (n=46)</th>
<th>Nimodipine (n=41)</th>
<th>$P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>28 (61)</td>
<td>22 (54)</td>
<td>0.497</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>8 (17)</td>
<td>9 (22)</td>
<td>0.143</td>
</tr>
<tr>
<td>Alcohol, n (%)</td>
<td>11 (24)</td>
<td>8 (20)</td>
<td>0.620</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>14 (30)</td>
<td>11 (27)</td>
<td>0.631</td>
</tr>
<tr>
<td>Age (years), mean ± SD</td>
<td>62±9</td>
<td>60±8</td>
<td>0.684</td>
</tr>
<tr>
<td>Weight (kg), mean ± SD</td>
<td>62±10</td>
<td>65±11</td>
<td>0.523</td>
</tr>
<tr>
<td>HR (bpm), mean ± SD</td>
<td>88±25</td>
<td>91±25</td>
<td>0.820</td>
</tr>
<tr>
<td>GCS (scores), mean ± SD</td>
<td>9±3</td>
<td>9±2</td>
<td>0.417</td>
</tr>
<tr>
<td>SBP (mmHg), mean ± SD</td>
<td>176±17</td>
<td>172±19</td>
<td>0.399</td>
</tr>
<tr>
<td>Hematoma volume (mL), mean ± SD</td>
<td>29±11</td>
<td>31±10</td>
<td>0.352</td>
</tr>
<tr>
<td>ICP (mmHg), mean ± SD</td>
<td>18±8</td>
<td>14±6</td>
<td>0.186</td>
</tr>
<tr>
<td>History of hypertension, n (%)</td>
<td>33 (72)</td>
<td>31 (75)</td>
<td>0.411</td>
</tr>
</tbody>
</table>

**Abbreviations:** GCS, Glasgow Coma Scale; HR, heart rate; ICP, intracerebral pressure; SBP, systolic blood pressure; SD, standard deviation.
In the NC group, 93.5% (43/46) patients achieved goal BP, while 6.5% (3/46) patients failed and received nitroprusside for BP control; similarly, 87.8% (36/41) NM patients achieved goal BP, with 12.2% (5/41) individuals failing and receiving nitroprusside. Therefore, the proportions of patients achieving the BP target or requiring additional antihypertensive agent were not statistically different between the two groups ($P=0.361$).

BP variability between both groups is shown in Figure 4. Patients in the NC group spent 87%±6% of the time at goal BP values, corresponding to 85%±7% obtained for NM individuals. Although this percentage was slightly higher in the NC group, the differences between both groups were not statistically significant ($P=0.139$). Of note, hypotension (SBP <90 mmHg) was not recorded during treatment with either agent.

Table 3 Hemodynamic indices recorded over time for both groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Time after drug infusion (minutes)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>15</td>
<td>30</td>
<td>45</td>
<td>60</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>Nicardipine</td>
<td>176±17</td>
<td>164±18</td>
<td>155±14</td>
<td>146±11</td>
</tr>
<tr>
<td></td>
<td>Nimodipine</td>
<td>172±19</td>
<td>169±17</td>
<td>162±21</td>
<td>151±14</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>Nicardipine</td>
<td>88±25</td>
<td>88±24</td>
<td>88±22</td>
<td>87±25</td>
</tr>
<tr>
<td></td>
<td>Nimodipine</td>
<td>91±25</td>
<td>91±19</td>
<td>90±22</td>
<td>90±23</td>
</tr>
<tr>
<td>ICP (mmHg)</td>
<td>Nicardipine</td>
<td>18±6</td>
<td>18±6</td>
<td>16±6</td>
<td>16±6</td>
</tr>
<tr>
<td></td>
<td>Nimodipine</td>
<td>14±6</td>
<td>15±4</td>
<td>16±6</td>
<td>16±5</td>
</tr>
</tbody>
</table>

Note: Values are expressed as mean ± SD.

Abbreviations: HR, heart rate; ICP, intracranial pressure; SBP, systolic blood pressure; SD, standard deviation.

In addition, the mean time to goal BP in the NC group was 43±18 minutes, showing no significant difference with the value obtained for NM patients (48±16 minutes) ($P=0.868$). Analysis of time to goal SBP demonstrated that both NC and NM were able to help reach the BP goal within the first hour of administration (Figure 5).

An intention-to-treat analysis showed that the mean number of dose adjustments required to maintain the goal BP was slightly lower in the NC group (8±2 times) than in NM patients (9±2 times) during IV infusion, although the difference was not statistically significant ($P=0.910$) (Figure 6).

A total of seven of 32 (21.9%) patients with ICH within 6 hours of symptom onset in the NC group underwent hematoma expansion (more than 33% increase in hematoma size), as measured by follow-up cerebral computed...
However, a new recommendation from the Acute Cerebral Hemorrhage (ATACH) trial, another trial, the Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH) trial, and the American Heart Association/American Stroke Association recommend a goal BP of less than 160/90 mmHg. Therefore, the guidelines for the management of ICH from the appropriate control of BP remains controversial. For outcomes to those of NC.

The efficacy and safety of IV NM administration of NM lowered BP promptly. However, a decrease in SBP, in comparison with placebo, for patients with ischemic stroke. In the NICU, we also found that IV NM treatment resulted in a statistically significant decrease in SBP, in comparison with placebo, for patients with ischemic stroke. In the NICU, we also found that IV NM administration of NM lowered BP promptly. However, trials exploring the antihypertensive effect of IV NM are scarce. The efficacy and safety of IV NM administration was assessed by comparing its clinical antihypertensive outcomes to those of NC.

In the treatment of hypertension in patients with ICH, the appropriate control of BP remains controversial. For instance, the guidelines for the management of ICH from the American Heart Association/American Stroke Association recommend a goal BP of less than 160/90 mmHg. However, a new recommendation from the Acute Cerebral Hemorrhage Trial (INTERACT) suggests that in patients with SBP of 150 to 220 mmHg, acute lowering of systolic BP to 140 mmHg is probably safe. INTERACT was undertaken with 404 patients, mostly Chinese, with ICH within 6 hours of onset, and the results showed a reduced hematoma growth, with no excess of neurological deterioration or other adverse events after controlling SBP to <140 mmHg. Elsewhere, SBP between 140 and 150 mmHg within 12 hours of ICH was reported to be associated with higher mortality. Consequently, according to INTERACT, we chose to reduce and maintain SBP between 120 and 140 mmHg in the present study. In the whole process, CPP was maintained above 70 mmHg.

Specifically, five patients in the NM group failed to achieve the goal BP. We found that the pretreatment SBP for all five patients reached values >200 mmHg. To verify these findings, we next selected eight other patients with SBP >200 mmHg upon admission who received IV NM to control SBP, and we found that only one patient achieved goal. When NC was chosen instead of NM to control SBP, the patients were more likely to reach the SBP target, and only one patient failed to achieve the goal. Despite the small sample size, we recommend that NM could be beneficial with SBP <200 mmHg. However, more comprehensive and rigorous studies are needed to further explore the best applicable scope of NM in treating hypertension.

Patients spent the majority of time at goal, and no differences were found in BP variability between both groups. Indeed, patients in both groups spent greater percentage of time above goal parameters in this study. Both drugs rarely caused hypotension symptoms: when the BP goal was reached, drug doses were gradually reduced or discontinued, and hypotension (SBP <90 mmHg) did not occur during the course of our treatment.

Intracranial hematoma expands in the acute phase, and increased hematoma is one of the main causes of neurological deterioration. Brott et al showed that the growth of intracranial hematoma occurred in 26% of patients within 4 hours after the first symptoms, and another 12% had such growth within the following 20 hours. The time between onset of symptoms and treatment may be an important predictor of hemorrhage growth. Since hemorrhage expansion most likely happened during a time window, timely therapeutic intervention may lower the incidence of hematoma expansion and subsequent mortality and disability. Furthermore, INTERACT and another trial, the Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH) trial, have confirmed that early rapid BP lowering is feasible and safe in patients with ICH. In this retrospective study, a significant decrease in SBP was obtained after treatment, with both drugs ($P<0.001$), and most

![Figure 6 Mean number of dose adjustments.](image-url)

**Figure 6** Mean number of dose adjustments.
patients achieved the SBP goal within 1 hour. All patients underwent follow up, by CT scan, 24 hours after admission. A total seven of 32 (21.9%) patients with ICH within 6 hours of symptom onset underwent hematoma expansion during NC infusion, and six of 33 (18.2%) such patients were recorded after NM treatment. Specifically, hematoma expansion in this trial was defined as a 33% increase in hematoma volume at 24 hours in comparison with baseline, as measured by image analysis on a CT. Neurological status was evaluated by GCS score, and neurological deterioration was defined by a decline in GCS by at least 2 points. In all, 13 of the 46 (28.3%) patients in the NC group suffered neurological deterioration, and so did eleven of the 41 (26.8%) patients in the NM group. The incidences of hematoma expansion and neurological deterioration described herein were lower compared with previous studies.23,26 Indeed, IV administration of NC and NM did not increase the rates of hematoma expansion and neurological deterioration.

Elevated BP leads to high perfusion pressure, which may increase ICP, while reducing BP results in auto-regulatory vasodilatation of cerebral vessels, which may also increase ICP.27,28 In the present study, ICP declined \( P=0.048 \) during IV administration of NC but increased \( P=0.066 \) after NM treatment. Guidelines for the management of spontaneous ICH from the American Heart Association/American Stroke Association and guidelines for the management of subarachnoid hemorrhage recommended IV NC as the preferred antihypertensive agent not affecting ICP. Nishiyama et al.29 found that NC decreased ICP, although it was still higher than normal, in patients with acute cerebral hemorrhage. Schmidt et al.30 reported an ICP increase of 3 (0–10) mmHg \( P<0.05 \) under treatment with NM, in patients with normal pressure hydrocephalus. Kotwica and Persson31 found the same trend, with IV infusion of NM leading to elevation of ICP in a rat model. However, Aslan et al.32 found lower ICP in NM-treated individuals compared with controls (without NM) \( P<0.001 \), in patients with severe head trauma. Our results, along with those of Nishiyama et al and Schmidt et al.29,30 suggest that NC and NM lead to reduction and elevation of ICP, respectively, when administered intravenously. Cerebral vasodilatation caused by NM may lead to raised ICP. Furthermore, elevated ICP did not lead to neurological deterioration in the NM group.

There are some limitations in our study. The first is the goal BP (SBP <140 mmHg), which is lower than that in the guidelines by the American Heart Association/American Stroke Association and other studies.10,11,33 Secondly, the ICH volume in our study was less than 60 mL, and the range of GCS scores was 3–15, so GCS scores of 3 or 4 were not included in our study which may not be complete and accurate when assessing therapeutic response of both agents after infusion. Finally, the sample size (87 patients) was small. A larger, prospective, and randomized study is required to further explore the full effects of NM.

**Conclusion**

This retrospective study confirms that NM is effective and safe in maintaining BP within goal, in patients with ICH in the NICU setting. Although NC individuals had better maintenance of BP, a higher percentage of patients achieving the BP goal, higher percentage of time spent within goal, less time to goal BP, fewer dose adjustments, and fewer additional medications for BP control, the differences were not statistically significant for these clinical outcomes between both groups.

**Acknowledgment**

The authors thank professor Qian Yang for his thorough proofreading and valuable comments.

**Author contributions**

BLW, LHL, WF, LT, and YQL initially designed the study. YQL, WF, LT, ML, YLY, YFG, SNG, LG, BZ, ZHL, and WZ participated in collecting the clinical information. YQL, WF, BLW, ML, YLY, YFG, SNG, and LT analyzed the clinical data and performed the statistical analysis. YQL, WF, LT, LHL, and BLW drafted or contributed to the writing of the manuscript. ML, YLY, YFG, SNG, LG, BZ, ZHL, and WZ read and approved the final manuscript.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Neuropsychiatric Disease and Treatment

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsychINFO’ database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

Neuropsychiatric Disease and Treatment 2015:11

1238

submit your manuscript | http://www.dovepress.com

Dovepress

Neuropsychiatric Disease and Treatment